Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients

• author:yirui
• date:2015-09-23
• click:

Findings: Total costs were 32% lower for the diagnostic-driven strategy (£1561.29) versus the empirical strategy

(£2301.93) due to a reduced incidence of adverse events and decreased use of antifungal therapy. Administration

of antifungal therapy was reduced by 41% (diagnostic-driven strategy, 74 of 1000; empirical strategy, 125 of 1000),

 with similar survival rates.

 

Implications: This study suggests that a diagnostic-driven strategy is likely to be cost-saving versus empirical

treatment for immunocompromised patients with persistent or recurrent neutropenic fevers.

 

 

                                                   Rosemary Barnes, MD et al. Clinical Therapeutics/Volume 37, Number 6, 2015.